PolyPid PYPD
NASDAQ PYPD
$5.20 -0.13 (-2.44%)
At close: Sep 9, 2026 · 4:00 PM EDT

PolyPid (PYPD) Income towards Parent Company (2019 - 2026)

PolyPid's (PYPD) quarterly Income towards Parent Company came in at $7.8 million in Q2 2026, down 20.55% year-over-year from $9.9 million in Q2 2025, and up 1.49% quarter-over-quarter from $7.7 million in Q1 2026.

Analysis

PolyPid (PYPD) Income towards Parent Company (2019 - 2026) Analysis & Trends

PolyPid has disclosed Income towards Parent Company across 8 years of filings, most recently posting $7.8 million for Q2 2026.

  • In Q2 2026, Income towards Parent Company fell 20.55% year-over-year to $7.8 million; the TTM figure through Jun 2026 stood at $31.6 million (down 7.92% YoY), while the FY2025 annual figure was $34.2 million, up 695702547.66% from the prior year.
  • Income towards Parent Company came in at $7.8 million for Q2 2026 at PolyPid, up from $7.7 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $11.9 million in Q1 2022 to a low of $5.6 million in Q3 2023.
  • Average Income towards Parent Company over 5 years is $7.9 million, with a median of $7.7 million recorded in 2024.
  • Year-over-year, Income towards Parent Company plunged 52.18% in 2022 and soared 56.93% in 2025.
  • Over 5 years, Income towards Parent Company stood at $6.5 million in 2022, then fell by 1.84% to $6.3 million in 2023, then soared by 34.02% to $8.5 million in 2024, then gained by 1.66% to $8.6 million in 2025, then declined by 9.17% to $7.8 million in 2026.
  • Per Business Quant data, the three most recent Income towards Parent Company figures were $7.8 million in Q2 2026, $7.7 million in Q1 2026, and $8.6 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 PolyPid 85.52 Mn 78.75 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 7.84 Mn
Mar 31, 2026 7.73 Mn
Dec 31, 2025 8.64 Mn
Sep 30, 2025 7.41 Mn
Jun 30, 2025 9.87 Mn
Mar 31, 2025 8.25 Mn
Dec 31, 2024 8.49 Mn
Sep 30, 2024 7.72 Mn
Jun 30, 2024 6.29 Mn
Mar 31, 2024 6.43 Mn
Dec 31, 2023 6.34 Mn
Sep 30, 2023 5.55 Mn
Jun 30, 2023 5.82 Mn
Mar 31, 2023 6.02 Mn
Dec 31, 2022 6.46 Mn
Sep 30, 2022 9.12 Mn
Jun 30, 2022 11.85 Mn
Mar 31, 2022 11.87 Mn
Dec 31, 2021 13.50 Mn
Sep 30, 2021 9.94 Mn